Microorganisms that live on the human skin also referred to as skin microbiome, can protect the skin from hostile invasions, support the recovery from skin diseases such as atopic dermatitis, acne, and rosacea, and may also increase wound healing.
Bayer and Azitra announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partners will use Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Bayer will provide formulations that can maintain Staphylococcus epidermidis viability while showing excellent skin compatibility and sensorial performance.
Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skincare products under a future License Agreement. Potential areas of application include medicated skincare products for sensitive, eczema-prone skin, as well as therapeutic products for skin diseases such as atopic dermatitis. In addition, Bayer will review the use of Azitra’s genetically modified bacteria in dermatology and other consumer health areas such as nutritionals and digestive health.